medigraphic.com
ISSN 0016-3813 (Impreso)

2016, Número 5

<< Anterior Siguiente >>

Gac Med Mex 2016; 152 (5)


Manifestaciones cutáneas en enfermedad inflamatoria intestinal

Chavez-Álvarez S, Gómez-Flores M, Ocampo-Candiani J

Idioma: Español
Referencias bibliográficas: 52
Paginas: 622-630
Archivo PDF: 279.00 Kb.


RESUMEN

La enfermedad inflamatoria intestinal (EII), destacando la colitis ulcerativa crónica inespecífica (CUCI) y la enfermedad de Crohn, han aumentado su incidencia en las últimas décadas. Tiene múltiples manifestaciones extra-intestinales, entre ellas las asociadas a la piel que aparecen la mayor parte de las ocasiones posterior al cuadro clínico intestinal. Estas se clasifican en: lesiones granulomatosas, dermatosis reactivas, las asociadas al tratamiento farmacológico de la EII y otras dermatosis. En el presente artículo presentaremos el abordaje clínico y de laboratorio, la fisiopatogenia, el tratamiento y la evolución esperada de estas manifestaciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324(2):84-8. Tabla 4. Manifestaciones cutáneas secundarias a medicamentos Medicamento Dermatosis secundarias Anti-TNF Granuloma anular, dermatitis reaccional medicamentosa, vasculitis leucocitoclástica, LES, psoriasis, lesiones eccematosas, carcinoma escamocelular o linfoma de células T o B10,16,51. Azatioprina Dermatitis reaccional medicamentosa, urticaria, angioedema, prurito o carcinoma escamocelular16,52. Ciclosporina Hiperplasia gingival, acné, verrugas virales, hiperplasias sebáceas, púrpura, vasculitis leucocitoclástica, carcinoma escamocelular o linfoma16,25. Esteroides Infección cutánea, reacción acneiforme, atrofia, telangiectasias, estrías, redistribución de la grasa o hipertricosis10,16,25. 6-mercaptopurina Alopecia, hiperpigmentación de piel y uñas, úlceras de mucosa oral o carcinoma escamocelular16,52. Metotrexato Úlceras en mucosa oral y piel, NET, acné, onicolisis, fototoxicidad, pseudolinfoma o carcinoma escamocelular16. Sulfasalazina/ Mesalazina/ Sulfapiridina Liquen plano, urticaria, vasculitis16.

  2. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55(5):401-12.

  3. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23(1):29-34.

  4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34.

  5. Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68(2):211. e1-33; quiz 244-6.

  6. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-9.

  7. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114(5):912-22.

  8. Moravvej H, Razavi GM, Farshchian M, Malekzadeh R. Cutaneous Manifestations in 404 Iranian Patients With Inflammatory Bowel Disease: A Retrospective Study. Indian J Dermatol Venereol Leprol. 2009;74(6): 607-10.

  9. Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87(5):281-93.

  10. Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:13.

  11. Ott C. Extraintestinal manifestations and complications in IBD. Nature reviews. Gastroenterol Hepatol. 2013;10:585-95.

  12. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn’s disease. Can J Gastroenterol. 2005;19(10):603-6.

  13. Tavarela-Veloso F. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004;4:50.

  14. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81(959):580-5.

  15. Jose FA, Heyman MB. Extraintestinal manifestations of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2008;46(2):124-33.

  16. Georgiou S, Pasmatzi E, Monastirli A, Tsambaos D. Cutaneous manifestations of inflammatory bowel disease. Hosp Chron. 2006;1:158-68.

  17. Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 1998;4(2):142-8.

  18. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26(3):265-73.

  19. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40 Suppl 2:S253-9.

  20. Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R. Erythema Nodosum: An Experience of 10 Years. Scand J Infect Dis. 2004; 36(6-7):424-7.

  21. Goudet P, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF. Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg. 2001;18(1):51-5.

  22. Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012;86 Suppl 1:28-35.

  23. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25(6):406-10.

  24. Field EA, Allan RB. Review article: oral ulceration – aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment Pharmacol Ther. 2003;18:949-62.

  25. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-36.

  26. Patil SA, Cross RK. Update in the management of extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2013;15(3):314.

  27. Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol. 2005;52(3 Pt 1):500-8.

  28. Al Roujayee A. Cutaneous manifestations of inflammatory bowel disease. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association. 2007;13:159-62.

  29. Neesse A, Michl P, Kunsch S, Ellenrieder V, Gress TM, Steinkamp M. Simultaneous onset of ulcerative colitis and disseminated pyoderma gangrenosum. Case Rep Gastroenterol. 2007;1(1):110-5.

  30. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17(22):2702-7.

  31. Su W, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43:790-800.

  32. Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases. 2013;1(2):74-8.

  33. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351(9102):581-5.

  34. Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013; 45(2):202-10.

  35. Patel F, Fitzmaurice S, Duong C, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol. 2015;95(5):525-31.

  36. Hegarty AM, Barrett AW, Scully C. Pyostomatitis Vegetans. Clin Exp Dermatol. 2004;29(1):1-7.

  37. Femiano F, Lanza A, Buonaiuto C, Perillo L, Dell’Ermo A, Cirillo N. Pyostomatitis vegetans: a review of the literature. Med Oral Patol Oral Cir Bucal. 2009;14(3):E114-7.

  38. Guhl G, Garcia-Diez A. Subcutaneous sweet syndrome. Dermatol Clin. 2008;26(4):541-51, viii-ix.

  39. Ytting H, Vind I, Bang D, Munkholm P. Sweet’s syndrome--an extraintestinal manifestation in inflammatory bowel disease. Digestion. 2005;72 (2-3):195-200.

  40. Ali M. Ulcerative colitis and Sweet’s syndrome: a case report and review of the literature. Can J Gastroenterol. 2008;22:296.

  41. Cohen PR, Kurzrock R. Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42(10):761-78.

  42. Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn’s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010;16(8):1431-42.

  43. Ghazi LJ, Schwartz DA. Perianal Crohn’s Disease—A Gastroenterologist’s Perspective. Semin Colon Rectal Surg. 2012;23(3):117- 124.

  44. Gligorijevic V, Spasic ´ N, Bojic ´ D, et al. The role of pelvic MRI in assesment of combined surgical and infliximab treatment for perianal Crohn’s disease. Acta Chir Iugosl. 2010;57(3):89-95.

  45. Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology. 2001;121(5):1064-72.

  46. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003;9(2):98-103.

  47. Sands BE, Bernstein CN, Chey WY, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876-85.

  48. Vaid RM, Cohen BA. Cutaneous Crohn’s disease in the pediatric population. Pediatr Dermatol. 2010;27(3):279-81.

  49. Barret M, de Parades V, Battistella M, Sokol H, Lemarchand N, Marteau P. Crohn’s disease of the vulva. J Crohns Colitis. 2014;8(7):563-70.

  50. Rigopoulos D, Larios G, Katsambas A. Skin signs of systemic diseases. Clin Dermatol. 2011;29(5):531-40.

  51. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048- 55.

  52. Ramiscal J, Brewer J. Thiopurines and risk of nonmelanoma skin cancer in inflammatory bowel disease. JAMA Dermatol. 2013;149:92.




2020     |     www.medigraphic.com